Detalles de la búsqueda
1.
Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients.
Br J Clin Pharmacol
; 85(4): 704-714, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30566758
2.
MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.
J Pharmacokinet Pharmacodyn
; 45(6): 787-802, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30415351
3.
Temporal pharmacokinetic/pharmacodynamic interaction between human CD3ε antigen-targeted monoclonal antibody otelixizumab and CD3ε binding and expression in human peripheral blood mononuclear cell static culture.
J Pharmacol Exp Ther
; 355(2): 199-205, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26341624
4.
Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes.
Clin Transl Sci
; 15(4): 1014-1026, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34962074
5.
A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine.
Pharmaceutics
; 12(12)2020 Dec 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33302490
6.
Multinomial logistic functions in markov chain models of sleep architecture: internal and external validation and covariate analysis.
AAPS J
; 13(3): 445-63, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21691915
Resultados
1 -
6
de 6
1
Próxima >
>>